While the primary endpoint of the study is Xgeva’s safety profile, secondary endpoints include time to disease progression and the proportion of patients without any surgery at six months. Amgen said ...

Xgeva (denosumab) is a prescription drug used to treat certain bone conditions and prevent bone complications in people with cancer. Xgeva’s cost may depend on factors such as your dosage and whether ...

Xgeva (denosumab) is a prescription drug that’s used to treat some kinds of cancer. Xgeva comes as a solution inside prefilled, disposable pens that’s injected under the skin. It’s usually given once ...

"We now finally have evidence that bone-targeted treatment is not only successful in treating bony metastases and preventing treatment-induced bone loss," said Michael Gnant. A follow-up analysis of ...

These are just a few of the more common side effects reported by people who received Xgeva in clinical trials. These side effects can vary, depending on the condition that the drug is being used to ...

Maggie is an Xgeva patient who has continued to dance throughout her cancer diagnosis and subsequent metastases. (Amgen) A breast cancer diagnosis is devastating. To hear that it has metastasized ...

Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the ...

Amgen, Inc. AMGN announced that the FDA has approved its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva. Xgeva is currently approved for the prevention of ...

Amgen today announced the FDA plans to decide by April 26 on its application to expand the use of its bone treatment drug Xgeva to prevent or delay the spread of advanced prostate cancer. The drug is ...

A panel of cancer experts voted against a new use for Amgen’s Xgeva in prostate cancer on Wednesday, saying the drug’s ability to slow the spread of the disease did not translate into meaningful ...

(Reuters) - U.S. health regulators rejected the application by Amgen Inc, the world's biggest biotechnology company, to expand the use of the drug Xgeva to delay the spread of tumors to the bone in ...